Here is a print in case you don’t do Facebook
Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight
Key Takeaways from the Non-Alcoholic Steatohepatitis Market Report
According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
Leading non-alcoholic steatohepatitis companies such as Merck & Co., Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, Madrigal Pharmaceuticals, Inc., Galmed Research and Development, Ltd., Galectin Therapeutics Inc., Zydus Therapeutics, Rivus Pharmaceuticals, Inc., Lipocine Inc., Enyo Pharma, HighTide Biopharma, Sagimet Biosciences Inc., Poxel SA, NGM Biopharmaceuticals, Inc., Boston Pharmaceuticals, Pfizer, AstraZeneca, Kowa Research Institute, Inc., Gilead Sciences, Inventiva Pharma, Cirius Therapeutics, Inc., Novo Nordisk A/S, 89bio, Inc., Akero Therapeutics, Inc., CytoDyn, Inc., NorthSea Therapeutics BV, Hepion Pharmaceuticals, Inc., Viking Therapeutics, Inc., Terns, Inc., Hepagene (Shanghai) Co., Ltd., Cascade Pharmaceuticals, Inc., Hanmi Pharmaceutical Company Limited, and others are developing novel NASH drugs that can be available in the NASH market in the coming years.
The promising non-alcoholic steatohepatitis therapies in the pipeline include Efinopegdutide (MK-6024), Tirzepatide, Resmetirom (MGL-3196), Aramchol Meglumine, GR-MD-02 (belapectin), Saroglitazar Magnesium, HU6, LPCN 1144, Vonafexor (EYP001), HTD1801, Denifanstat (TVB-2640), PXL065, Aldafermin (NGM282), BOS-580, Ervogastat (PF-06865571) + Clesacostat (PF-05221304), Mitiperstat (AZD4831), Semaglutide, Pemafibrate (K-877-ER)/ Tofogliflozin (CSG-452), Semaglutide, Cilofexor, and Firsocostat, Lanifibranor (IVA337), MSDC-0602K, NNC0194 0499 (FGF-21), BIO89-100 (Pegozafermin), Efruxifermin (AKR-001), Leronlimab (PRO 140), Icosabutate, Rencofilstat, VK2809, TERN-501 ± TERN-101, HPG1860, CS0159 (linafexor), HM15211 (efocipegtrutide), and others.
Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.
Innovative therapeutic classes like FXR agonists, THR-ß agonists, FGF modulators, PPAR modulators, GLP-1 receptor agonists, FASN inhibitors, CCR5 antagonists, FFAR4 agonists, and others are reshaping the pharmaceutical landscape. Expected regulatory approvals indicate substantial NASH market expansion, fueled by the potential of these advanced treatments to address diverse medical conditions, paving the way for significant post-approval market growth.
Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight
Key Takeaways from the Non-Alcoholic Steatohepatitis Market Report
According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
Leading non-alcoholic steatohepatitis companies such as Merck & Co., Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, Madrigal Pharmaceuticals, Inc., Galmed Research and Development, Ltd., Galectin Therapeutics Inc., Zydus Therapeutics, Rivus Pharmaceuticals, Inc., Lipocine Inc., Enyo Pharma, HighTide Biopharma, Sagimet Biosciences Inc., Poxel SA, NGM Biopharmaceuticals, Inc., Boston Pharmaceuticals, Pfizer, AstraZeneca, Kowa Research Institute, Inc., Gilead Sciences, Inventiva Pharma, Cirius Therapeutics, Inc., Novo Nordisk A/S, 89bio, Inc., Akero Therapeutics, Inc., CytoDyn, Inc., NorthSea Therapeutics BV, Hepion Pharmaceuticals, Inc., Viking Therapeutics, Inc., Terns, Inc., Hepagene (Shanghai) Co., Ltd., Cascade Pharmaceuticals, Inc., Hanmi Pharmaceutical Company Limited, and others are developing novel NASH drugs that can be available in the NASH market in the coming years.
The promising non-alcoholic steatohepatitis therapies in the pipeline include Efinopegdutide (MK-6024), Tirzepatide, Resmetirom (MGL-3196), Aramchol Meglumine, GR-MD-02 (belapectin), Saroglitazar Magnesium, HU6, LPCN 1144, Vonafexor (EYP001), HTD1801, Denifanstat (TVB-2640), PXL065, Aldafermin (NGM282), BOS-580, Ervogastat (PF-06865571) + Clesacostat (PF-05221304), Mitiperstat (AZD4831), Semaglutide, Pemafibrate (K-877-ER)/ Tofogliflozin (CSG-452), Semaglutide, Cilofexor, and Firsocostat, Lanifibranor (IVA337), MSDC-0602K, NNC0194 0499 (FGF-21), BIO89-100 (Pegozafermin), Efruxifermin (AKR-001), Leronlimab (PRO 140), Icosabutate, Rencofilstat, VK2809, TERN-501 ± TERN-101, HPG1860, CS0159 (linafexor), HM15211 (efocipegtrutide), and others.
Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.
Innovative therapeutic classes like FXR agonists, THR-ß agonists, FGF modulators, PPAR modulators, GLP-1 receptor agonists, FASN inhibitors, CCR5 antagonists, FFAR4 agonists, and others are reshaping the pharmaceutical landscape. Expected regulatory approvals indicate substantial NASH market expansion, fueled by the potential of these advanced treatments to address diverse medical conditions, paving the way for significant post-approval market growth.
6
